Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to perform the first fracture reduction clinical trial with a
potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term
care population.
Phase:
Phase 4
Details
Lead Sponsor:
Susan L. Greenspan University of Pittsburgh
Collaborators:
National Institute on Aging (NIA) National Institutes of Health (NIH)
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Vitamin D Vitamins Zoledronic Acid